Graft versus host disease (GVHD)

Hematopoietic Stem Cell Transplantation (HSCT) Webinars

Posted on July 29, 2015 by admin

Supportive Care Post Allo Transplant: Schooling, Pets & Immunizations etc., in Addition to Diet and Isolation Practices

Presenters:

Sarah Courtney, RN(EC), MN, NP-Pediatrics
Pediatrics; Blood and Marrow Transplant Unit
SickKids, Toronto, ON

Tal Schechter-Finkelstein, MD
Staff Physician, Blood and Marrow Transplant Unit
SickKids, Toronto, ON

Rivanna Stuhler, RD
Clinical Dietitian
SickKids, Toronto, ON

Click here to view this webinar or search www.webcast.otn.ca for archived event #33128987
This webinar was presented live on February 19, 2014. Information presented and speaker credentials were accurate at the time of the live presentation.

Acute Graft Versus Host Disease: Pathophysiology, Diagnosis, Staging and Therapy

Presenters:

Jeff Lipton, PhD, MD, FRCPC
Professor of Medicine, University of Toronto
Director, Allogeneic Blood and Marrow Transplant Service
Princess Margaret Cancer Centre, Toronto, ON

Laura McGillis, MN, BScN
Nurse Practitioner, Allogeneic Bone Marrow Transplant
Princess Margaret Cancer Centre, Toronto, ON

Click here to view this webinar or search www.webcast.otn.ca for archived event #36053907

This webinar was presented live on June 25, 2014. Information presented and speaker credentials were accurate at the time of the live presentation.

Long-Term Health-Related Outcomes in Survivors of Childhood Hematopoietic Cell Transplantation

Posted on March 6, 2014 by admin

Presentation Description:
HCT is frequently offered as a curative option for children with benign and malignant conditions. Improvements in HCT strategies have increased survival by approximately 10% per decade. In fact, long-term survival is an expected outcome for many children and adolescents who undergo HCT. The growing population of long-term survivors has brought to the medical forefront a host of chronic and debilitating conditions attributed to toxicity from pre-transplantation exposure, transplantation conditioning regimens, chronic immunosuppression, and GVHD. This presentation provided an overview of health-related outcomes in long-term survivors of childhood HCT, and compared these outcomes to survivors of conventionally treated cancer.

Speaker:

Saro Armenian, DO, MPH
Medical Director, Pediatric Survivorship Clinic, Childhood Cancer Survivorship Program
City of Hope, Los Angeles

Understanding Acute GVHD: Linking Clinical Science to the Bedside

Posted on February 1, 2013 by admin

Presentation Description: Graft versus host disease (GVHD) remains the major complication of allogeneic bone marrow transplantation (BMT), but until recently there have been no laboratory biomarkers for GVHD. One new plasma biomarker for GVHD of the gastrointestinal tract, Regenerative 3c (REG3o), has significant diagnostic and prognostic value. This presentation described one approach to the discovery and validation of such biomarkers and analyzed their potential for use in developing new grading schemes with improved risk-stratification of patients.

Speaker:

James L.M. Ferrara, MD, DSc.
Director
Combined Adult and Pediatric Blood and Marrow Transplant Program
University of Michigan Cancer Center, Michigan, USA

POGO

Blog

Tag: Graft versus host disease (GVHD)

Hematopoietic Stem Cell Transplantation (HSCT) Webinars

Supportive Care Post Allo Transplant: Schooling, Pets & Immunizations etc., in Addition to Diet and Isolation Practices

Acute Graft Versus Host Disease: Pathophysiology, Diagnosis, Staging and Therapy

Long-Term Health-Related Outcomes in Survivors of Childhood Hematopoietic Cell Transplantation

Understanding Acute GVHD: Linking Clinical Science to the Bedside